MedPath

Intensive versus Conventional Therapy to Slow the Progression of Idiopathic Glomerular Diseases

Phase 4
Completed
Conditions
progression renal disease due to Idiopathic Glomerular Diseases
Renal and Urogenital - Kidney disease
Registration Number
ACTRN12610000034033
Lead Sponsor
ASL6 Spedali Riuniti Livorno
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
130
Inclusion Criteria

Patients with estimated GFR>30 mL/min/1.73 m2 (36-102 mL/min/1.73 m2), Patients included had a clinical diagnosis of idiopathic chronic glomerulonephritis with urine protein >1g/g creatinine, confirmed at least in two separate occasions.

Exclusion Criteria

Patients with membranous glomerulonephritis and minimal change disease were excluded because of the possibility of spontaneous remission and the unpredictable response of these patients to treatment. Patients with diabetes mellitus, renovascular or malignant hypertension, secondary glomerular disease, rapidly progressive glomerulonephritis, malignancies, myocardial infarction, or cerebrovascular accident within the 6 months preceding the study, congestive heart failure, hepatic dysfunction, serum potassium >5 mEq/l, eGFR<30 ml/min/1.73m2, and a history of intolerance to angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers ( ARBs) . We excluded patients treated with steroids, nonsteroidal anti-inflammatory drugs, or immunosuppressive agents within 6 months preceeding the study and patients previously treated with these drugs and achieving long period of remission.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Effects on proteinuria ( urine albumin-to creatinine ratio)[3 years following randomisation]
Secondary Outcome Measures
NameTimeMethod
Effects on eGFR ( estimated glomerular filtration rate) Blood anlysis and calculated formula[3 years following randomisation]
© Copyright 2025. All Rights Reserved by MedPath